Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)

NCT00720109 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00720109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00720109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Completed
Start date
July 14, 2008
Completion date
March 31, 2020
Enrollment
63 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, childhood b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1